Clinical Trials Logo

VWD - Von Willebrand's Disease clinical trials

View clinical trials related to VWD - Von Willebrand's Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT05437536 Recruiting - Clinical trials for VWD - Von Willebrand's Disease

The Severe Von Willebrand Disease (sVWD) Patient Registry

Start date: December 10, 2021
Phase:
Study type: Observational [Patient Registry]

A web-based registry will be created by the sponsor, VWD Connect Foundation (VCF), to collect data on patients with severe Von Willebrand Disease (sVWD). Data will be self-reported by patients and/or collected by registry personnel, as appropriate. The purpose of the sVWD Patient Registry is to create a database of well-characterized (with respect to demographics, medical history, symptoms, laboratory and genetic data, etc.) patients with sVWD for participation in retrospective and prospective research.

NCT ID: NCT04106908 Recruiting - Clinical trials for VWD - Von Willebrand's Disease

Effectiveness and Tolerability of Eqwilate in Real-life Conditions

Start date: November 27, 2019
Phase:
Study type: Observational

MOdalities of use, effectiveNEss and TOlerability of Eqwilate® a balanced combInatiON of VWF and FVIII in von WillEbrand patients in real-life conditions: the ONE-TO-ONE study

NCT ID: NCT03896997 Not yet recruiting - Clinical trials for VWD - Von Willebrand's Disease

Update in VWD Laboratory Diagnosis

Start date: January 2020
Phase:
Study type: Observational

The present study will focus on the investigation of the global contribution and limitations of the multimeric analysis and mutation analysis in the VWD diagnostic process. 1. To quantify the bleeding symptoms using bleeding assessment tools (BAT) which has developed by The International Society on Thrombosis and Haemostasis (ISTH) and correlate it to the diagnosis of different subtypes of VWD in Egyptian population. 2. To assess the utility of (gain of function mutant GpIbα binding) as a recent functional assay that measures VWF activity in VWD patients. 3. Clarify how the recent laboratory diagnostic modalities are required to streamline diagnosis , classification and improve treatment of VWD patients. 4. Explore how the molecular analysis can resolve many of the drawbacks and limitations of phenotyping diagnosis (in Egyptian population which not studied before).